MedTrace Logo

Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

NCT01635777 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-07-10

No results posted yet for this study

Summary

Miltefosine efficacy will be \>85%

Conditions

  • PKDL

Interventions

DRUG

Miltefosine

2.5 mg/kg/day for 12 weeks

DRUG

Miltefosine

2.5 mg/kg/day for 8 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-10-31
Completion
2010-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635777 on ClinicalTrials.gov